{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:46:22Z","timestamp":1789613182622,"version":"build-2803163510"},"reference-count":33,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,4,18]],"date-time":"2019-04-18T00:00:00Z","timestamp":1555545600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","award":["R21 CA191647"],"award-info":[{"award-number":["R21 CA191647"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000005","name":"Department of Defense","doi-asserted-by":"crossref","award":["W81XWH-14-0258"],"award-info":[{"award-number":["W81XWH-14-0258"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0590-4","type":"journal-article","created":{"date-parts":[[2019,4,18]],"date-time":"2019-04-18T09:07:39Z","timestamp":1555578459000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Treatment of malignant pleural effusions: the case for localized immunotherapy"],"prefix":"10.1136","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6723-3330","authenticated-orcid":false,"given":"Albert D.","family":"Donnenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Luketich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev","family":"Dhupar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera S.","family":"Donnenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,4,18]]},"reference":[{"key":"590_CR1","doi-asserted-by":"crossref","unstructured":"Clive AO, Kahan BC, Hooper CE, Bhatnagar R, Morley AJ, Zahan-Evans N, et al. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax. 2014.","DOI":"10.1136\/thoraxjnl-2014-205285"},{"issue":"5","key":"590_CR2","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1164\/ajrccm.162.5.ats8-00","volume":"162","author":"S American Thoracic","year":"2000","unstructured":"American Thoracic S. Management of malignant pleural effusions. Am J Respir Crit Care Med. 2000;162(5):1987\u20132001.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"590_CR3","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.athoracsur.2007.11.039","volume":"85","author":"WH Warren","year":"2008","unstructured":"Warren WH, Kalimi R, Khodadadian LM, Kim AW. Management of malignant pleural effusions using the Pleur(x) catheter. Ann Thorac Surg. 2008;85(3):1049\u201355.","journal-title":"Ann Thorac Surg"},{"issue":"20","key":"590_CR4","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1056\/NEJM197211162872004","volume":"287","author":"JC Ruckdeschel","year":"1972","unstructured":"Ruckdeschel JC, Codish SD, Stranahan A, McKneally MF. Postoperative empyema improves survival in lung cancer. Documentation and analysis of a natural experiment. N Engl J Med. 1972;287(20):1013\u20137.","journal-title":"N Engl J Med"},{"issue":"2","key":"590_CR5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/BF00199131","volume":"22","author":"W Bakker","year":"1986","unstructured":"Bakker W, Nijhuis-Heddes JM, van der Velde EA. Post-operative intrapleural BCG in lung cancer: a 5-year follow-up report. Cancer Immunol Immunother. 1986;22(2):155\u20139.","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"590_CR6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s002620050407","volume":"45","author":"H Yanagawa","year":"1997","unstructured":"Yanagawa H, Haku T, Hiramatsu K, Nokihara H, Takeuchi E, Yano S, et al. Intrapleural instillation of interferon gamma in patients with malignant pleurisy due to lung cancer. Cancer Immunol Immunother. 1997;45(2):93\u20139.","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"590_CR7","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1200\/JCO.2004.09.164","volume":"22","author":"S Sartori","year":"2004","unstructured":"Sartori S, Tassinari D, Ceccotti P, Tombesi P, Nielsen I, Trevisani L, et al. Prospective randomized trial of intrapleural bleomycin versus interferon alfa-2b via ultrasound-guided small-bore chest tube in the palliative treatment of malignant pleural effusions. J Clin Oncol. 2004;22(7):1228\u201333.","journal-title":"J Clin Oncol"},{"issue":"5","key":"590_CR8","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1038\/bjc.1995.501","volume":"72","author":"SH Goey","year":"1995","unstructured":"Goey SH, Eggermont AM, Punt CJ, Slingerland R, Gratama JW, Oosterom R, et al. Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study. Br J Cancer. 1995;72(5):1283\u20138.","journal-title":"Br J Cancer"},{"issue":"2","key":"590_CR9","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0169-5002(00)00192-6","volume":"31","author":"B Castagneto","year":"2001","unstructured":"Castagneto B, Zai S, Mutti L, Lazzaro A, Ridolfi R, Piccolini E, et al. Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: results of a phase II study on 31 consecutive patients. Lung Cancer. 2001;31(2):303\u201310.","journal-title":"Lung Cancer"},{"issue":"8","key":"590_CR10","first-page":"4587","volume":"37","author":"H Chu","year":"2017","unstructured":"Chu H, Du F, Gong Z, Lian P, Wamg Z, Li P, et al. Better clinical efficiency of TILs for malignant pleural effusion and ascites than cisplatin through Intrapleural and intraperitoneal infusion. Anticancer Res. 2017;37(8):4587\u201391.","journal-title":"Anticancer Res"},{"issue":"12","key":"590_CR11","first-page":"4569","volume":"31","author":"K Maeda","year":"2011","unstructured":"Maeda K, Hazama S, Tokuno K, Kan S, Maeda Y, Watanabe Y, et al. Impact of chemotherapy for colorectal Cancer on regulatory T-cells and tumor immunity. Anticancer Res. 2011;31(12):4569\u201374.","journal-title":"Anticancer Res"},{"key":"590_CR12","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13058-016-0737-x","volume":"18","author":"NL Mani","year":"2016","unstructured":"Mani NL, Schalper KA, Hatzis C, Saglam O, Tavassoli F, Butler M, et al. Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer. Breast Cancer Res. 2016;18:78.","journal-title":"Breast Cancer Res"},{"key":"590_CR13","doi-asserted-by":"crossref","unstructured":"Khanna S, Thomas A, Abate-Daga D, Zhang J, Morrow B, Steinberg SM, et al. Malignant mesothelioma effusions are infiltrated by CD3+ T cells highly expressing PD-L1 and the PD-L1+ tumor cells within these effusions are susceptible to ADCC by the anti-PD-L1 antibody Avelumab. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016.","DOI":"10.1016\/j.jtho.2016.07.033"},{"issue":"10","key":"590_CR14","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1002\/ijc.30289","volume":"139","author":"L Li","year":"2016","unstructured":"Li L, Yang L, Wang L, Wang F, Zhang Z, Li J, et al. Impaired T cell function in malignant pleural effusion is caused by TGF-beta derived predominantly from macrophages. Int J Cancer. 2016;139(10):2261\u20139.","journal-title":"Int J Cancer"},{"issue":"1_supplement","key":"590_CR15","first-page":"1036.3-.3","volume":"25","author":"S Amasheh","year":"2011","unstructured":"Amasheh S, Markov AG, Volgin GN, Voronkova MA, Yablonsky PK, Fromm M. Barrier function of human pleura mesothelium is constituted by tight junctions. FASEB J. 2011;25(1_supplement):1036.3-.3.","journal-title":"FASEB J"},{"issue":"3","key":"590_CR16","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1136\/thx.34.3.389","volume":"34","author":"L Telvi","year":"1979","unstructured":"Telvi L, Jaubert F, Eyquem A, Andreux JP, Labrousse F, Chretien J. Study of immunoglobulins in pleura and pleural effusions. Thorax. 1979;34(3):389\u201392.","journal-title":"Thorax."},{"key":"590_CR17","volume-title":"Application of large-pore microdialysis in interstitial sampling of therapeutic monoclonal antibody. Clinical pharmacology in drug development","year":"2017","unstructured":"Khaowroongrueng V, Jadhav SB, Fueth M, Otteneder MB, Richter W, Derendorf H, editors. Application of large-pore microdialysis in interstitial sampling of therapeutic monoclonal antibody. Clinical pharmacology in drug development. San Diego, CA: Wiley; 2017."},{"issue":"140","key":"590_CR18","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1183\/16000617.0019-2016","volume":"25","author":"I Psallidas","year":"2016","unstructured":"Psallidas I, Kalomenidis I, Porcel JM, Robinson BW, Stathopoulos GT. Malignant pleural effusion: from bench to bedside. Eur Respir Rev. 2016;25(140):189.","journal-title":"Eur Respir Rev"},{"issue":"2","key":"590_CR19","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1378\/chest.110.2.433","volume":"110","author":"Y-M Chen","year":"1996","unstructured":"Chen Y-M, Yang W-K, Whang-Peng J, Kuo BI-T, Perng R-P. Elevation of Interleukin-10 levels in malignant pleural effusion. Chest. 1996;110(2):433\u20136.","journal-title":"Chest."},{"issue":"2","key":"590_CR20","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.lungcan.2012.03.006","volume":"77","author":"CE Hooper","year":"2012","unstructured":"Hooper CE, Elvers KT, Welsh GI, Millar AB, Maskell NA. VEGF and sVEGFR-1 in malignant pleural effusions: association with survival and pleurodesis outcomes. Lung Cancer. 2012;77(2):443\u20139.","journal-title":"Lung Cancer"},{"issue":"6","key":"590_CR21","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1016\/j.chest.2016.01.001","volume":"149","author":"R Thomas","year":"2016","unstructured":"Thomas R, Cheah HM, Creaney J, Turlach BA, Lee YCG. Longitudinal measurement of pleural fluid biochemistry and cytokines in malignant pleural effusions. Chest. 2016;149(6):1494\u2013500.","journal-title":"Chest."},{"issue":"1","key":"590_CR22","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1046\/j.1365-2249.1997.d01-889.x","volume":"107","author":"P Dore","year":"1997","unstructured":"Dore P, Lelievre E, Morel F, Brizard A, Fourcin M, Clement C, et al. IL-6 and soluble IL-6 receptors (sIL-6R and sgp130) in human pleural effusions: massive IL-6 production independently of underlying diseases. Clin Exp Immunol. 1997;107(1):182\u20138.","journal-title":"Clin Exp Immunol"},{"issue":"11","key":"590_CR23","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/ncb3041","volume":"16","author":"H Lu","year":"2014","unstructured":"Lu H, Clauser KR, Tam WL, Frose J, Ye X, Eaton EN, et al. A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages. Nat Cell Biol. 2014;16(11):1105\u201317.","journal-title":"Nat Cell Biol"},{"issue":"6","key":"590_CR24","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1165\/ajrcmb.14.6.8652179","volume":"14","author":"S Fujino","year":"1996","unstructured":"Fujino S, Yokoyama A, Kohno N, Hiwada K. Interleukin 6 is an autocrine growth factor for normal human pleural mesothelial cells. Am J Respir Cell Mol Biol. 1996;14(6):508\u201315.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"5","key":"590_CR25","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/ni.2262","volume":"13","author":"D Malhotra","year":"2012","unstructured":"Malhotra D, Fletcher AL, Astarita J, Lukacs-Kornek V, Tayalia P, Gonzalez SF, et al. Transcriptional profiling of stroma from inflamed and resting lymph nodes defines immunological hallmarks. Nat Immunol. 2012;13(5):499\u2013510.","journal-title":"Nat Immunol"},{"key":"590_CR26","doi-asserted-by":"crossref","unstructured":"Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington SM, et al. PD-L1 expression in triple negative breast Cancer. Cancer Immunol Res. 2014.","DOI":"10.1158\/2326-6066.CIR-13-0127"},{"issue":"5","key":"590_CR27","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.bbamcr.2011.01.034","volume":"1813","author":"J Scheller","year":"2011","unstructured":"Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 2011;1813(5):878\u201388.","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"590_CR28","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1158\/0008-5472.CAN-10-1496","volume":"71","author":"C-W Lo","year":"2011","unstructured":"Lo C-W, Chen M-W, Hsiao M, Wang S, Chen C-A, Hsiao S-M, et al. IL-6 trans-signaling in formation and progression of malignant ascites in ovarian Cancer. Cancer Res. 2011;71(2):424.","journal-title":"Cancer Res"},{"issue":"6","key":"590_CR29","doi-asserted-by":"crossref","first-page":"6626","DOI":"10.18632\/oncotarget.6570","volume":"7","author":"SO Lee","year":"2016","unstructured":"Lee SO, Yang X, Duan S, Tsai Y, Strojny LR, Keng P, et al. IL-6 promotes growth and epithelial-mesenchymal transition of CD133+ cells of non-small cell lung cancer. Oncotarget. 2016;7(6):6626\u201338.","journal-title":"Oncotarget."},{"issue":"6","key":"590_CR30","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1200\/JCO.2012.44.2020","volume":"31","author":"K Ando","year":"2013","unstructured":"Ando K, Takahashi F, Motojima S, Nakashima K, Kaneko N, Hoshi K, et al. Possible role for tocilizumab, an anti\u2013Interleukin-6 receptor antibody, in treating Cancer Cachexia. J Clin Oncol. 2013;31(6):e69\u201372.","journal-title":"J Clin Oncol"},{"issue":"16","key":"590_CR31","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507\u201317.","journal-title":"N Engl J Med"},{"key":"590_CR32","first-page":"17","volume-title":"Negative co-receptors and ligands","author":"H-T Jin","year":"2011","unstructured":"Jin H-T, Ahmed R, Okazaki T. Role of PD-1 in regulating T-cell immunity. In: Ahmed R, Honjo T, editors. Negative co-receptors and ligands. Berlin, Heidelberg: Springer Berlin Heidelberg; 2011. p. 17\u201337."},{"issue":"6","key":"590_CR33","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/j.1365-2125.2010.03635.x","volume":"69","author":"P Ruf","year":"2010","unstructured":"Ruf P, Kluge M, Jager M, Burges A, Volovat C, Heiss MM, et al. Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients. Br J Clin Pharmacol. 2010;69(6):617\u201325.","journal-title":"Br J Clin Pharmacol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0590-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0590-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0590-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,6]],"date-time":"2020-12-06T19:07:32Z","timestamp":1607281652000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0590-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,18]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["590"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0590-4","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,18]]},"assertion":[{"value":"3 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"110"}}